6.1 Tc-99m Cardiac Imaging Agents
Key Takeaways
- Tc-99m sestamibi and tetrofosmin localize in myocardium by passive diffusion and mitochondrial retention proportional to blood flow and viable myocytes
- Typical adult MPI doses are roughly 8–12 mCi for rest and 24–36 mCi for stress in a one-day protocol (or ~20–30 mCi each in two-day protocols); image 15–60 min after injection
- Tc-99m PYP binds calcium-rich damaged myocardium and is used for cardiac amyloid (ATTR) imaging and, historically, acute infarct avid imaging
- Tc-99m labeled RBCs (UltraTag® kit or in vivo/modified in vivo PYP method) are used for MUGA (ERNA) and GI bleeding scans
- Key traps: free Tc-99m pertechnetate stomach/thyroid activity; poor RBC labeling; wrong imaging window after stress; confusing PYP amyloid protocol with old infarct-only timing
6.1 Tc-99m Cardiac Imaging Agents
Quick Answer: Sestamibi (Cardiolite®) and tetrofosmin (Myoview®) are lipophilic cationic MPI agents retained in myocyte mitochondria in proportion to blood flow and viability. PYP images cardiac amyloid and (classically) acute infarct. Labeled RBCs support MUGA and GI bleed studies. Master mechanisms, doses, routes, imaging times, and free-Tc / labeling traps.
Pair each cardiac agent with mechanism, indication, typical activity, and high-yield pitfalls.
Myocardial Perfusion Imaging: Sestamibi and Tetrofosmin
Mechanisms
Both Tc-99m sestamibi and Tc-99m tetrofosmin are lipophilic cations. After IV injection they distribute to myocardium in proportion to regional coronary blood flow. Uptake is by passive diffusion; intracellular retention is largely in mitochondria. Viable myocytes retain tracer; scar does not. Unlike Tl-201, clinically important redistribution is minimal—a stress injection “freezes” the stress flow pattern for later imaging.
| Feature | Tc-99m sestamibi (Cardiolite®) | Tc-99m tetrofosmin (Myoview®) |
|---|---|---|
| Class | Isonitrile (MIBI) | Diphosphine |
| Localization | Passive diffusion + mitochondrial retention | Similar passive uptake / retention |
| Hepatic clearance | Often higher early liver activity | Often faster hepatobiliary clearance |
| Typical use | Rest/stress MPI; also parathyroid, breast (historical) | Rest/stress MPI |
| Admin | IV | IV |
Both allow gated SPECT for wall motion and EF with better counts than Tl-201.
Indications
Detection and risk stratification of CAD, preoperative risk assessment, known CAD follow-up, and selected viability protocols.
Typical Adult Doses and Imaging Times
Lab protocols vary; exam items use rounded clinic norms:
| Protocol pattern | Rest activity (approx.) | Stress activity (approx.) | Imaging time after injection |
|---|---|---|---|
| One-day rest-stress | ~8–12 mCi (300–444 MBq) | ~24–36 mCi (888–1332 MBq) | Rest ~30–60 min; stress ~15–45 min (tetrofosmin often earlier) |
| Two-day equal dose | ~20–30 mCi each day | Same order | Similar delays |
| Stress-only (selected low-risk) | — | ~25–40 mCi | ~15–45 min |
Route: IV (often via the stress-lab line). Inject at peak treadmill exercise or at peak pharmacologic hyperemia (adenosine, regadenoson, dipyridamole) or appropriate dobutamine timing. Prep traps: caffeine abstinence for vasodilator stress; hold selected meds only when ordered; use a secure IV because extravasation creates a hot pocket and falsely low myocardial counts.
Image Quality Traps (MPI)
High subdiaphragmatic liver/bowel activity obscures the inferior wall—wait longer, hydrate, use a fatty snack/coffee per protocol, or re-image. Soft-tissue attenuation (breast, diaphragm) and patient motion mimic fixed or reversible defects; always review rotating projections and gated wall-motion data before calling a scar.
Tc-99m Pyrophosphate (PYP): Infarct Avid and Amyloid
Tc-99m PYP binds calcium-rich tissue. Classic use was acute infarct avid imaging (peak sensitivity roughly 24–72 h after onset). Current high-yield use is cardiac ATTR amyloidosis: planar and SPECT show myocardial uptake scored vs rib.
| Item | Typical practice |
|---|---|
| Activity | ~15–25 mCi (555–925 MBq) IV |
| Imaging | Often 1 hour and/or 3 hours after injection (protocol-dependent) |
| Key interpretation | Myocardial uptake vs bone; SPECT separates blood-pool from myocardium |
| Trap | Blood-pool activity at early times can mimic myocardial uptake—delayed SPECT matters |
PYP is not a first-line CAD perfusion agent. Do not substitute it for sestamibi/tetrofosmin on “chest pain rule-out CAD” items unless the stem targets infarct avid or amyloid.
Labeled Red Blood Cells: MUGA and GI Bleed
Tc-99m RBCs remain in the blood pool when labeling efficiency is high.
Labeling Methods
- In vitro (UltraTag® kit) — highest labeling efficiency (often ≥95%); preferred when quality is critical.
- Modified in vivo — inject PYP (stannous ion), withdraw blood into a syringe with Tc-99m, incubate, reinject.
- In vivo — inject PYP, then inject Tc-99m pertechnetate; lowest efficiency, more free Tc.
Stannous ion (Sn²⁺) reduces Tc so it binds hemoglobin; too little tin, oxidizing meds, or excess free Tc leave pertechnetate that goes to stomach, thyroid, and salivary glands.
Clinical Uses
| Study | Role of Tc-99m RBCs | Typical adult activity |
|---|---|---|
| MUGA / ERNA | Gated blood-pool EF and wall motion | ~20–30 mCi |
| GI bleeding scan | Active bleed accumulates focus of activity that moves | ~20–30 mCi |
| Hemangioma / blood-pool | Characterize vascular lesions | Protocol-dependent |
MUGA prep: stable ECG gating; avoid free Tc that confuses stomach with heart border. GI bleed: sequential imaging; a positive study shows activity that appears and moves through bowel—static “blush” without movement may be artifact or non-bleed.
Safety Notes and Contraindications
Pregnancy and breastfeeding policies apply to all Tc-99m cardiac agents (follow institutional/NRC guidance on delay and interruption of nursing). Kit-component allergy is rare but guides product choice. For labeled blood products: positive patient ID, aseptic technique, and same-patient reinjection only—never mix patients. Recent transfusion or oxidizing medications can impair RBC labeling; suspect a poor label whenever stomach, thyroid, or salivary glands light up on a “blood-pool” study.
Agent Selection Cheat Sheet
| Clinical goal | Preferred Tc-99m approach |
|---|---|
| Stress/rest perfusion CAD | Sestamibi or tetrofosmin SPECT |
| LVEF blood pool (MUGA) | Labeled RBCs |
| Active GI bleed | Labeled RBCs |
| Cardiac ATTR amyloid | PYP planar + SPECT |
| Acute infarct avid (selected) | PYP at appropriate delay |
Memorize the mechanism–indication–dose–time tetrad. Exam items often swap one element (wrong imaging time, or PYP ordered for routine MPI).
What is the primary mechanism of myocardial localization for Tc-99m sestamibi?
On a Tc-99m labeled RBC MUGA study, prominent stomach and thyroid activity most strongly suggests which technical problem?
Which statement best matches current clinical use of Tc-99m pyrophosphate (PYP) in cardiology?